insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal

metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily

Type 2 Diabetes Mellitus

metformin and sitagliptin

insulin glargine and insulin lispro

insulin lispro given three times daily with meals

Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit

Participants will be followed for the duration of the hospital stay, an expected average of 5 days.

Participants will be followed for the duration of the hospital stay, an expected average of 5 days. The outcome is the percent of patients having any blood glucose value less than 70 mg/dl during their hospital stay.

Participants will be followed for the duration of the hospital stay, an expected average of 5 days. The outcome is the percent of patients who develop acute kidney injury during their hospital stay. Acute kidney injury is defined as an absolute increase in the serum creatinine concentration of ≥ 0.3 mg/dL from baseline or a percentage increase in the serum creatinine concentration of ≥ 50%

Rush University Medical Center

Linagliptin 5 mg tablets daily for 4 days

Type 2 Diabetes

Chronic Renal Failure

Linagliptin

Placebo

University Hospital Diabetes Outpatient Clinic

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Rapid Effects of the DPP-4 Inhibitor Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetic Patients With and Without Chronic Renal Failure. A Randomized Cross-over Trial Versus Placebo

Evaluate whether 4-days Linagliptin treatment, compared to placebo, significantly reduces the M1/M2 ratio in type 2 diabetic patients. In this cross-over design trial, Linagliptin and placebo will be administered once daily for 4 consecutive days to 30 type 2 diabetic patients with or without renal failure with a 2 week washout period in between.

Evaluate whether 4-days Linagliptin treatment, compared to placebo, significantly modifies the concentrations of selected cytokines and chemokines (MCP-1, RANTES, SDF-1a, IL-1, IL-6, TNF-a, IL-10, TGF-beta, CCL22, fraktalkine) in type 2 diabetic patients. In this cross-over design trial, Linagliptin and placebo will be administered once daily for 4 consecutive days to 30 type 2 diabetic patients with and without renal failure with a 2 week washout period in between. As the number of measures is high and there is no adjustment for multiple testing, this outcome is to be considered exploratory.

Evaluate whether 4-days Linagliptin treatment, compared to placebo, significantly modifies the levels of CD34+KDR+ EPCs (outcome added in course)

University of Padova

starting with vildagliptin for 30 days followed by placebo for 30 days

starting with placebo for 30 days followed by vildagliptin for 30 days

SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors

Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo

peptidase/hypoxia

Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).

O mais completo banco de dados de ervas medicinais apoiado pela ciência